
OUR JOURNEY
From strategy to
measurable action
The year connected long-term direction with practical resources, research and global engagement.
APR–JUN 2025
Evidence
shared globally
Patient-reported research was presented at AACR and EHA, while new collaborations strengthened the evidence base.
JUL–SEP 2025
Awareness
and advocacy
The Honest Talk campaign reached millions, while policy resources expanded.
OCT–DEC 2025
Community
convened
Global Summit 2025 in Amsterdam helped Members turn lived experience and data into advocacy action.
JAN–MAR 2026
Participation
at scale
The tenth Global Patient Survey closed with 9,991 responses in 21 languages.
ABOUT LYMPHOMA COALITION
Lymphoma Coalition is the leading global coalition of patient organisations dedicated to supporting people affected by lymphoma and chronic lymphocytic leukaemia (CLL).
Through research, education, advocacy and collaboration, the Coalition helps ensure that patient experiences remain central to healthcare decision-making.
A trusted global voice for people affected by lymphoma and CLL
Welcome to our new Members
Hong Kong Cancer Information

Vision
A better future for everyone impacted by lymphoma.
Mission
To generate and provide trusted information, knowledge and best practices that influence and make equitable care possible.
STRATEGIC DIRECTION
Building the future
of lymphoma care
Strategy 2025–2030 provides a clear pathway for applying what Lymphoma Coalition learns from patient experiences to achieve meaningful, measurable and actionable impact.
Influence policy to improve optimal care
Support policy initiatives that improve access, quality of care and health equity.
Deliver usable evidence and information
Translate research and education into practical action.
Empower patient leaders and organisations
Build capacity and amplify patient voices.
Connect diverse stakeholders
Bring together patients, clinicians, researchers, industry and policymakers.
Ensure impact at every level
Make global evidence useful in regional and local contexts.
Explore Strategy 2025–2030 →
CONNECTING THE GLOBAL COMMUNITY
Learning together.
Acting together.
Global programmes created space for patient leaders to
exchange knowledge, strengthen advocacy and reach people
in the languages and communities that matter to them.
Global Summit 2025
In Amsterdam, Members and partners explored how lived experience, credible evidence and collaboration can strengthen patient advocacy.
Explore the Global Summit →


Karen Van Rassel
Leadership Award
APCL was recognised for patient-centred support, national advocacy and sustainable programmes improving lymphoma care in Portugal.
Read the award story →
World Lymphoma Awareness Day
Honest Talk reached 10,238,197 people, with Member voices featured in eight languages and five local scholarships supporting action across three continents.
Watch the campaign video →

Local scholarship recipients:
ADVANCING PATIENT-CENTRED CARE
Shared frameworks.
Stronger evidence.
Two major initiatives helped connect patient priorities with practical action in care, advocacy, research and policy.
Lymphoma Patient Charter

Explore the Charter →
A global framework supporting timely diagnosis, equitable access, supportive care and meaningful involvement in healthcare decisions.
Timely diagnosis
Shared decision-making
Reliable information
Psychosocial support
Survivorship care
Patient involvement
Discover the GPS →
Global Patient Survey 2026
The tenth survey transformed lived experience into actionable evidence across diverse healthcare systems.
9,991
responses
21
languages
24
country reports



GENERATING EVIDENCE AND DRIVING CHANGE
Patient experience at the centre of research
FY2026 research explored treatment experience, quality of life, psychosocial wellbeing, shared decision-making, diagnostic pathways and access to care.
Shared decision-making by treatment in LBCL
Analysis from the 2024 Global Patient Survey.
CAR T-cell patient experience
Watch the oral research presentation.
Shared decision-making by biological sex in DLBCL
Patient-reported differences that can inform care.
Treatment attributes in follicular lymphoma
What patients value in treatment decisions.
Side effects and trust in CLL treatment plans
The impact of symptoms that remain unaddressed.
Psychosocial impact of lymphoma and CLL treatment
Global insights from the patient perspective.
Clinical trial access and reimbursement in Europe
Bridging gaps for large B-cell lymphoma therapies.
Addressing unmet needs in GvHD
Recent research publication and patient priorities.
POLICY & ADVOCACY RESOURCES
Practical tools for stronger, evidence-informed advocacy

01
Patient organisations and health systems
Making visible the social and economic value patient organisations create.

02
Essential medicines
Examining affordability, accessibility and equity.

03
10 Steps to Data-Driven Advocacy
Turning GPS findings into focused advocacy.

04
Health technology assessment
Stronger patient participation in HTA.
COMMUNITY ADVISORY BOARDS (CABs)
Four international CABs
Structured opportunities with Incyte, Novartis, Roche and Takeda brought lived experience into research, education and programme development.
Follicular lymphoma
Shared decision-making
Hodgkin lymphoma
Quality of life
Large B-cell lymphoma
Supportive care
DLBCL
Access and HTA
STRENGTHENING PARTNERSHIPS AND COLLABORATION
Connecting patient insight with global expertise
Strategic alliances helped bring patient priorities
into clinical research, education, regulation, policy
and healthcare decision-making.
ESMO
Exploring the Association of Side Effects with Depression in Patients with Chronic Lymphocytic Leukaemia Who Have Received Treatment
ISPOR 2026
Patient-Reported Experiences with Cancer-Related Fatigue Following CAR T-Cell Therapy
EHA 2026
Incidence and Impact of Misdiagnosis in Diffuse Large B-Cell Lymphoma (DLBCL)
LOOKING AHEAD TO FY2027
Building on momentum
In FY2027, Lymphoma Coalition will continue advancing Strategy 2025–2030 and supporting people affected by lymphoma and CLL through evidence, advocacy, education and collaboration.
1
Publish GPS 2026 findings
Turn participation into evidence Members can use.
2
Implement the Patient Charter
Support practical conversations about access, quality and equity.
3
Expand policy and advocacy
Strengthen resources and capacity across the network.
4
Prepare WLAD and Global Summit 2026
Create new opportunities to connect, learn and act.

LEADERSHIP MESSAGE
A message from
Susan Thornton
“Our progress is a direct result of the resilience, collaboration and unwavering compassion of our Members and partners.”
Watch Susan Thornton, Board Chair, reflect on the year and the shared commitment behind Lymphoma Coalition’s global impact.
Susan Thornton · Board Chair · Lymphoma Coalition

Lymphoma Coalition extends its sincere gratitude to Member organisations, research partners, sponsors, patients and care partners.
This support and collaboration make progress possible for the global lymphoma and CLL community.
MEMBER ORGANISATIONS · RESEARCH PARTNERS · SPONSORS · PATIENTS · CARE PARTNERS
Thank you for making this impact possible
ACKNOWLEDGEMENTS
EXPLORE THE COMPLETE STORY
See every project, partnership and insight in the FY2026 Impact Report.
Download the full report for detailed results, research highlights and links to all featured resources.

A better future for everyone impacted by lymphoma.
Not-For-Profit Business Number: 803211465 · © Lymphoma Coalition